m-RECIST at 1 month and Child A are survival predictors after percutaneous ethanol injection of hepatocellular carcinoma

Imagem de Miniatura
Arquivos
art_SILVA_mRECIST_at_1_month_and_Child_A_are_2014.PDF (127.85 KB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2014
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MEXICAN ASSOC HEPATOLOGY
Autores
SILVA, Mauricio F.
CAMPOS, Luciana T.
DINIZ, Marcio A.
Citação
ANNALS OF HEPATOLOGY, v.13, n.6, p.796-802, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background and aims. Percutaneous ethanol injection (PEI) is a well-established therapeutic option in patients with cirrhosis and hepatocellular carcinoma (HCC). The modified-Response Evaluation Criteria in Solid Tumors (m-RECIST) are an important tool for the assessment of HCC response to therapy. The aim was to evaluate whether HCC response according to the m-RECIST criteria could be an effective predictor of Long-term survival in Barcelona Clinic Liver Cancer (BCLC) stage 0 and A HCC patients undergoing PEI. Material and methods. 79 patients were followed-up for median time of 26.8 months. HCC diagnosis was based on the,current guidelines of the American Association for Study of the Liver Diseases (AASLD) and European Association for Study of the Liver (EASL). Patient survival was calculated from the first PEI session to the end of the follow-up. Results. The 1-, 3-, and 5-year overall survival rates were 79, 48 and 37%, respectively. In the multivariate analysis, Child-Pugh-Turcotte (CPT) (p = 0.022) and the response to m-RECIST criteria (p = 0.016) were associated with patient survival. CPT A patients who achieved Complete Response (CR) 1 month after PEI presented a 5-year survival rate of 55%. By contrast, the worst scenario, the group with CPT B but without CR had a 5-year survival rate of 9%, while the group with either CPT A or CR as a survival predictor had a 5-year survival rate of 31%. In conclusion, in BCLC stage 0 and A HCC-patients, m-RECIST at 1 month and Child A may predict survival rates after PEI.
Palavras-chave
Liver cancer, Percutaneous ablation, Radiological response, Curative treatment, Clinical decision-making
URI
https://observatorio.fm.usp.br/handle/OPI/8982
Referências
  1. [Anonymous], 2012, J HEPATOL, V56, P908
  2. Bruix J, 2002, HEPATOLOGY, V35, P519, DOI 10.1053/jhep.2002.32089
  3. Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
  4. Brunello F, 2008, SCAND J GASTROENTERO, V43, P727, DOI 10.1080/00365520701885481
  5. Cho YK, 2009, HEPATOLOGY, V49, P453, DOI 10.1002/hep.22648
  6. Germani G, 2010, J HEPATOL, V52, P380, DOI 10.1016/j.jhep.2009.12.004
  7. Hou TI, 2003, SCAND J GASTROENTERO, V7, P770
  8. Khan KN, 2000, J HEPATOL, V32, P269, DOI 10.1016/S0168-8278(00)80072-0
  9. Kikuchi L, 2014, WORLD J GASTROENTERO, V20, P1585, DOI 10.3748/wjg.v20.i6.1585
  10. Kikuchi L, 2013, ANTIVIR THER, V18, P445, DOI 10.3851/IMP2602
  11. Kuang M, 2009, RADIOLOGY, V253, P552, DOI 10.1148/radiol.2532082021
  12. Lencioni R, 2010, HEPATOLOGY, V52, P762, DOI 10.1002/hep.23725
  13. Lencioni R, 2010, SEMIN LIVER DIS, V30, P52, DOI 10.1055/s-0030-1247132
  14. LENCIONI R, 1995, CANCER, V76, P1737, DOI 10.1002/1097-0142(19951115)76:10<1737::AID-CNCR2820761010>3.0.CO;2-P
  15. Lencioni RA, 2003, RADIOLOGY, V228, P235, DOI 10.1148/radiol.2281020718
  16. Lin SM, 2005, GUT, V54, P1151, DOI 10.1136/gut.2004.045203
  17. Lin SM, 2004, GASTROENTEROLOGY, V127, P1714, DOI 10.1053/j.gastro.2004.09.003
  18. LIVRAGHI T, 1992, CANCER, V69, P925, DOI 10.1002/1097-0142(19920215)69:4<925::AID-CNCR2820690415>3.0.CO;2-G
  19. Llovet JM, 1999, HEPATOLOGY, V30, P1434, DOI 10.1002/hep.510300629
  20. Llovet JM, 2008, J NATL CANCER I, V100, P698, DOI 10.1093/jnci/djn134
  21. Marrero JA, 2005, HEPATOLOGY, V41, P707, DOI 10.1002/hep.20636
  22. Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104
  23. Ohnishi K, 1998, HEPATOLOGY, V27, P67, DOI 10.1002/hep.510270112
  24. OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
  25. Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731
  26. Sala M, 2004, HEPATOLOGY, V40, P1352, DOI 10.1002/hep.20465
  27. Sherman M, 2010, ONCOLOGY-BASEL, V78, P7, DOI 10.1159/000315223
  28. Shiina S, 2005, GASTROENTEROLOGY, V129, P111
  29. Villa E, 2000, HEPATOLOGY, V32, P233, DOI 10.1053/jhep.2000.9603

Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - LIM/37
Carregar mais